Revenue
2019
2020
2021
2022
2023
2024
2025
Molecular Partners AG (MOLN)
Price$4.35Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | CHF0 | CHF5.0M | CHF7.0M | CHF189.6M | CHF9.8M | CHF9.3M | CHF20.4M |
| Research & development | CHF40.2M | CHF48.6M | CHF48.8M | CHF50.7M | CHF55.7M | CHF56.1M | CHF43.5M |
| Operating expenses | CHF58.1M | CHF66.2M | CHF68.1M | CHF73.0M | CHF73.2M | CHF67.7M | CHF57.0M |
| Operating income | −CHF58.1M | −CHF61.2M | −CHF61.1M | CHF116.6M | −CHF63.4M | −CHF58.3M | −CHF36.7M |
| Operating margin | — | −1,231.73% | −868.26% | 61.50% | −650.17% | −624.21% | −179.86% |
| EBITDA | −CHF56.0M | −CHF58.8M | −CHF58.7M | CHF119.0M | −CHF60.9M | −CHF55.4M | −CHF34.2M |
| EBITDA margin | — | −1,184.06% | −833.87% | 62.76% | −623.88% | −593.31% | −167.74% |
| Net income | −CHF61.7M | −CHF54.0M | −CHF62.0M | CHF117.9M | −CHF63.8M | −CHF62.8M | −CHF36.3M |
| Net profit margin | — | −1,087.38% | −880.70% | 62.16% | −653.94% | −671.70% | −178.03% |
| Basic EPSper basic share | -CHF 1.65 | -CHF 1.59 | -CHF 1.89 | CHF 3.63 | -CHF 2.06 | -CHF 2.51 | -CHF 1.69 |
| Diluted EPSper diluted share | -CHF 1.65 | -CHF 1.59 | -CHF 1.89 | CHF 3.54 | -CHF 2.06 | -CHF 2.51 | -CHF 1.69 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
MONTANOVA CAPITAL, LLC | 2.22M |
BVF INC/IL | 1.35M |
CITADEL ADVISORS LLC | 17.18K |
MORGAN STANLEY | 367 |
UBS Group AG | 279 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data